End-of-life (EOL) outcomes and healthcare utilization for patients with hepatocellular carcinoma (HCC) who received immune checkpoint inhibition (ICI).

Authors: Margaret Wheless, Anna-Carson Rimer Uhelski, Sarah Cimino, Henry Domenico, Sara F. Martin, Mohana Karlekar, Thatcher Heumann, Kristen Keon Ciombor, Laura Williams Goff, Rajiv Agarwal

Published: 2025-01-27

DOI: 10.1200/jco.2025.43.4_suppl.560

Source: Full article

---

Abstract

560